Share Price and Basic Stock Data
Last Updated: October 15, 2025, 5:05 pm
| PEG Ratio | -7.11 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Adeshwar Meditex Ltd operates in the medical equipment and accessories sector, with its recent share price standing at ₹16.20 and a market capitalization of ₹23.40 Cr. The company reported sales of ₹82.36 Cr for FY 2023, a notable increase from ₹64.76 Cr in FY 2022. This upward trend in revenue continued into FY 2025, with reported sales of ₹83.71 Cr. Quarterly sales figures also indicate a fluctuating yet generally positive trend, with ₹46.26 Cr in sales for Q2 FY 2024, a rise from ₹36.30 Cr in Q1 FY 2024. However, the company experienced some variability in quarterly performance, such as a decline to ₹33.59 Cr in Q1 FY 2025. This highlights the potential for growth, although the company must navigate fluctuations to maintain a consistent upward trajectory in revenues.
Profitability and Efficiency Metrics
Adeshwar Meditex Ltd’s profitability metrics reflect a mixed performance. The operating profit margin (OPM) stood at 5.82% for FY 2025, down from 6.34% in FY 2023, indicating a slight compression in margins. Net profit for FY 2023 was ₹2.07 Cr, with an earnings per share (EPS) of ₹1.43. The interest coverage ratio (ICR) was a healthy 3.47x, demonstrating that the company can comfortably meet its interest obligations, although a decline from previous years indicates a need for caution. The cash conversion cycle (CCC) was reported at 175.13 days, suggesting that the company takes a longer time to convert its investments in inventory and accounts receivable into cash. This extended CCC could be a potential risk, impacting liquidity and operational efficiency.
Balance Sheet Strength and Financial Ratios
The balance sheet of Adeshwar Meditex reflects a moderate financial position, with total borrowings reported at ₹12.45 Cr and reserves at ₹22.53 Cr, leading to a debt-to-equity ratio of 0.33. This ratio is relatively low, indicating a conservative approach to leverage, which bodes well for financial stability. Furthermore, the current ratio stood at 2.03, suggesting that the company has sufficient liquidity to cover its short-term liabilities. The return on equity (ROE) was reported at 5.51%, while the return on capital employed (ROCE) was 8.27%, both of which are modest compared to industry averages. The price-to-book value ratio (P/BV) is notably low at 0.65x, suggesting that the stock may be undervalued in the market, potentially providing an attractive entry point for investors looking for value.
Shareholding Pattern and Investor Confidence
Adeshwar Meditex’s shareholding pattern reveals a significant level of promoter ownership at 57.55%, indicating strong management control and commitment. The public holds 42.44% of the shares, reflecting a balanced distribution of ownership. The number of shareholders is reported at 188, which may suggest a relatively concentrated investor base. There are no reported foreign institutional investors (FIIs) or domestic institutional investors (DIIs), which could imply a lack of institutional interest that typically supports stock liquidity and price stability. The decline in public shareholding from 57.35% in FY 2022 to 42.44% in FY 2025 could raise questions about investor confidence, especially if it signals a trend of divestment by retail investors.
Outlook, Risks, and Final Insight
If margins sustain and the company effectively manages its cash conversion cycle, Adeshwar Meditex could leverage its current financial position to enhance profitability. However, the risks include the potential impact of fluctuating sales and the extended cash conversion cycle, which could strain liquidity. The absence of institutional backing also raises concerns about long-term investor confidence. Moreover, if the company can improve operational efficiency and reduce its CCC, it may enhance its profitability metrics. The solid promoter holding could act as a stabilizing factor, but the company must demonstrate consistent performance to attract institutional investors and bolster market confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Adeshwar Meditex Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Constronics Infra Ltd | 81.4 Cr. | 65.0 | 158/46.0 | 19.4 | 30.9 | 0.00 % | 19.7 % | 15.8 % | 10.0 |
| Centenial Surgical Suture Ltd | 35.7 Cr. | 97.8 | 189/82.2 | 84.3 | 0.00 % | 3.94 % | 4.64 % | 10.0 | |
| Adeshwar Meditex Ltd | 31.4 Cr. | 21.8 | 26.5/15.0 | 15.8 | 25.6 | 0.00 % | 8.27 % | 5.51 % | 10.0 |
| Poly Medicure Ltd | 19,305 Cr. | 1,905 | 3,358/1,821 | 54.0 | 273 | 0.18 % | 20.1 % | 15.8 % | 5.00 |
| Mohini Health & Hygiene Ltd | 88.9 Cr. | 48.8 | 86.9/46.0 | 8.61 | 57.8 | 0.00 % | 14.1 % | 10.0 % | 10.0 |
| Industry Average | 19,305.00 Cr | 427.68 | 24.45 | 94.32 | 0.04% | 13.22% | 10.35% | 9.00 |
Quarterly Result
| Metric | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 36.53 | 29.45 | 30.21 | 34.54 | 46.06 | 36.30 | 46.26 | 33.59 | 40.90 | 37.45 |
| Expenses | 34.90 | 26.47 | 28.12 | 33.25 | 43.33 | 33.84 | 44.05 | 30.61 | 38.90 | 35.27 |
| Operating Profit | 1.63 | 2.98 | 2.09 | 1.29 | 2.73 | 2.46 | 2.21 | 2.98 | 2.00 | 2.18 |
| OPM % | 4.46% | 10.12% | 6.92% | 3.73% | 5.93% | 6.78% | 4.78% | 8.87% | 4.89% | 5.82% |
| Other Income | 0.09 | 0.17 | 0.02 | 0.21 | 0.08 | 0.22 | 0.08 | 0.05 | 0.21 | 0.17 |
| Interest | 1.08 | 1.11 | 1.02 | 1.01 | 1.04 | 1.01 | 1.03 | 0.90 | 0.71 | 0.31 |
| Depreciation | 0.17 | 0.17 | 0.17 | 0.22 | 0.26 | 0.27 | 0.29 | 0.31 | 0.25 | 0.21 |
| Profit before tax | 0.47 | 1.87 | 0.92 | 0.27 | 1.51 | 1.40 | 0.97 | 1.82 | 1.25 | 1.83 |
| Tax % | 29.79% | 27.27% | 26.09% | 59.26% | 27.81% | 29.29% | 25.77% | 29.12% | 28.00% | 27.32% |
| Net Profit | 0.33 | 1.36 | 0.68 | 0.11 | 1.09 | 0.99 | 0.73 | 1.28 | 0.90 | 1.34 |
| EPS in Rs | 0.63 | 1.29 | 0.47 | 0.08 | 0.76 | 0.69 | 0.51 | 0.89 | 0.62 | 0.93 |
Last Updated: May 31, 2025, 7:10 am
Below is a detailed analysis of the quarterly data for Adeshwar Meditex Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 37.45 Cr.. The value appears to be declining and may need further review. It has decreased from 40.90 Cr. (Sep 2024) to 37.45 Cr., marking a decrease of 3.45 Cr..
- For Expenses, as of Mar 2025, the value is 35.27 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 38.90 Cr. (Sep 2024) to 35.27 Cr., marking a decrease of 3.63 Cr..
- For Operating Profit, as of Mar 2025, the value is 2.18 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Sep 2024) to 2.18 Cr., marking an increase of 0.18 Cr..
- For OPM %, as of Mar 2025, the value is 5.82%. The value appears strong and on an upward trend. It has increased from 4.89% (Sep 2024) to 5.82%, marking an increase of 0.93%.
- For Other Income, as of Mar 2025, the value is 0.17 Cr.. The value appears to be declining and may need further review. It has decreased from 0.21 Cr. (Sep 2024) to 0.17 Cr., marking a decrease of 0.04 Cr..
- For Interest, as of Mar 2025, the value is 0.31 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.71 Cr. (Sep 2024) to 0.31 Cr., marking a decrease of 0.40 Cr..
- For Depreciation, as of Mar 2025, the value is 0.21 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.25 Cr. (Sep 2024) to 0.21 Cr., marking a decrease of 0.04 Cr..
- For Profit before tax, as of Mar 2025, the value is 1.83 Cr.. The value appears strong and on an upward trend. It has increased from 1.25 Cr. (Sep 2024) to 1.83 Cr., marking an increase of 0.58 Cr..
- For Tax %, as of Mar 2025, the value is 27.32%. The value appears to be improving (decreasing) as expected. It has decreased from 28.00% (Sep 2024) to 27.32%, marking a decrease of 0.68%.
- For Net Profit, as of Mar 2025, the value is 1.34 Cr.. The value appears strong and on an upward trend. It has increased from 0.90 Cr. (Sep 2024) to 1.34 Cr., marking an increase of 0.44 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.93. The value appears strong and on an upward trend. It has increased from 0.62 (Sep 2024) to 0.93, marking an increase of 0.31.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:03 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 58.60 | 52.92 | 56.12 | 65.97 | 64.76 | 82.36 | 79.85 | 83.71 |
| Expenses | 52.96 | 47.44 | 50.64 | 61.22 | 61.39 | 77.14 | 74.66 | 79.29 |
| Operating Profit | 5.64 | 5.48 | 5.48 | 4.75 | 3.37 | 5.22 | 5.19 | 4.42 |
| OPM % | 9.62% | 10.36% | 9.76% | 7.20% | 5.20% | 6.34% | 6.50% | 5.28% |
| Other Income | 0.10 | 0.25 | 0.28 | 0.13 | 0.23 | 0.31 | 0.13 | 0.26 |
| Interest | 1.78 | 2.23 | 2.52 | 2.19 | 2.03 | 2.09 | 1.93 | 1.39 |
| Depreciation | 0.36 | 0.35 | 0.34 | 0.35 | 0.38 | 0.53 | 0.60 | 0.50 |
| Profit before tax | 3.60 | 3.15 | 2.90 | 2.34 | 1.19 | 2.91 | 2.79 | 2.79 |
| Tax % | 29.72% | 28.25% | 27.24% | 28.63% | 33.61% | 28.52% | 27.96% | 26.16% |
| Net Profit | 2.54 | 2.26 | 2.12 | 1.68 | 0.79 | 2.07 | 2.01 | 2.07 |
| EPS in Rs | 5.10 | 4.54 | 4.03 | 1.60 | 0.55 | 1.43 | 1.39 | 1.43 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -11.02% | -6.19% | -20.75% | -52.98% | 162.03% | -2.90% | 2.99% |
| Change in YoY Net Profit Growth (%) | 0.00% | 4.83% | -14.56% | -32.22% | 215.00% | -164.92% | 5.88% |
Adeshwar Meditex Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 9% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | 36% |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -10% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 6% |
| Last Year: | 6% |
Last Updated: September 5, 2025, 2:06 pm
Balance Sheet
Last Updated: September 10, 2025, 2:54 pm
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.98 | 4.98 | 5.27 | 10.53 | 14.43 | 14.43 | 14.43 | 14.43 |
| Reserves | 8.55 | 10.81 | 13.64 | 10.05 | 16.52 | 18.48 | 20.48 | 22.53 |
| Borrowings | 11.58 | 19.92 | 21.32 | 22.45 | 18.99 | 16.43 | 13.89 | 12.45 |
| Other Liabilities | 7.33 | 5.79 | 14.57 | 19.27 | 22.63 | 17.67 | 15.23 | 22.79 |
| Total Liabilities | 32.44 | 41.50 | 54.80 | 62.30 | 72.57 | 67.01 | 64.03 | 72.20 |
| Fixed Assets | 2.36 | 2.44 | 2.28 | 2.24 | 3.03 | 3.70 | 3.53 | 2.95 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.02 | 0.04 | 0.08 | 0.08 | 0.10 | 0.10 | 0.10 | 0.00 |
| Other Assets | 30.06 | 39.02 | 52.44 | 59.98 | 69.44 | 63.21 | 60.40 | 69.25 |
| Total Assets | 32.44 | 41.50 | 54.80 | 62.30 | 72.57 | 67.01 | 64.03 | 72.20 |
Below is a detailed analysis of the balance sheet data for Adeshwar Meditex Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 14.43 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 14.43 Cr..
- For Reserves, as of Mar 2025, the value is 22.53 Cr.. The value appears strong and on an upward trend. It has increased from 20.48 Cr. (Mar 2024) to 22.53 Cr., marking an increase of 2.05 Cr..
- For Borrowings, as of Mar 2025, the value is 12.45 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 13.89 Cr. (Mar 2024) to 12.45 Cr., marking a decrease of 1.44 Cr..
- For Other Liabilities, as of Mar 2025, the value is 22.79 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.23 Cr. (Mar 2024) to 22.79 Cr., marking an increase of 7.56 Cr..
- For Total Liabilities, as of Mar 2025, the value is 72.20 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 64.03 Cr. (Mar 2024) to 72.20 Cr., marking an increase of 8.17 Cr..
- For Fixed Assets, as of Mar 2025, the value is 2.95 Cr.. The value appears to be declining and may need further review. It has decreased from 3.53 Cr. (Mar 2024) to 2.95 Cr., marking a decrease of 0.58 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.10 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 0.10 Cr..
- For Other Assets, as of Mar 2025, the value is 69.25 Cr.. The value appears strong and on an upward trend. It has increased from 60.40 Cr. (Mar 2024) to 69.25 Cr., marking an increase of 8.85 Cr..
- For Total Assets, as of Mar 2025, the value is 72.20 Cr.. The value appears strong and on an upward trend. It has increased from 64.03 Cr. (Mar 2024) to 72.20 Cr., marking an increase of 8.17 Cr..
Notably, the Reserves (22.53 Cr.) exceed the Borrowings (12.45 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.94 | -14.44 | -15.84 | -17.70 | -15.62 | -11.21 | -8.70 | -8.03 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 108.69 | 134.63 | 181.26 | 150.82 | 183.06 | 123.78 | 115.51 | 152.52 |
| Inventory Days | 64.44 | 112.51 | 119.36 | 174.35 | 168.24 | 127.72 | 138.71 | 126.64 |
| Days Payable | 43.11 | 38.76 | 104.70 | 119.86 | 138.51 | 88.18 | 75.97 | 104.03 |
| Cash Conversion Cycle | 130.02 | 208.39 | 195.93 | 205.31 | 212.79 | 163.33 | 178.25 | 175.13 |
| Working Capital Days | 129.43 | 108.29 | 124.03 | 111.49 | 147.05 | 116.60 | 129.04 | 135.78 |
| ROCE % | 17.69% | 14.27% | 11.22% | 6.93% | 10.07% | 9.62% | 8.27% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.43 | 1.39 | 1.44 | 0.55 | 1.59 |
| Diluted EPS (Rs.) | 1.43 | 1.39 | 1.44 | 0.59 | 1.59 |
| Cash EPS (Rs.) | 1.78 | 1.81 | 1.80 | 0.81 | 1.92 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 25.61 | 24.19 | 22.81 | 21.45 | 19.54 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 25.61 | 24.19 | 22.81 | 21.45 | 19.54 |
| Revenue From Operations / Share (Rs.) | 58.01 | 55.33 | 57.07 | 44.87 | 62.64 |
| PBDIT / Share (Rs.) | 3.21 | 3.68 | 3.80 | 2.49 | 4.76 |
| PBIT / Share (Rs.) | 2.86 | 3.26 | 3.43 | 2.23 | 4.43 |
| PBT / Share (Rs.) | 1.94 | 1.93 | 2.01 | 0.82 | 2.36 |
| Net Profit / Share (Rs.) | 1.43 | 1.39 | 1.44 | 0.54 | 1.59 |
| PBDIT Margin (%) | 5.52 | 6.64 | 6.66 | 5.55 | 7.60 |
| PBIT Margin (%) | 4.93 | 5.89 | 6.01 | 4.96 | 7.08 |
| PBT Margin (%) | 3.33 | 3.48 | 3.52 | 1.83 | 3.76 |
| Net Profit Margin (%) | 2.46 | 2.51 | 2.51 | 1.22 | 2.54 |
| Return on Networth / Equity (%) | 5.58 | 5.75 | 6.30 | 2.56 | 8.14 |
| Return on Capital Employeed (%) | 10.49 | 12.96 | 13.89 | 9.06 | 17.68 |
| Return On Assets (%) | 2.86 | 3.13 | 3.09 | 1.09 | 2.69 |
| Long Term Debt / Equity (X) | 0.05 | 0.03 | 0.07 | 0.13 | 0.25 |
| Total Debt / Equity (X) | 0.33 | 0.39 | 0.44 | 0.55 | 0.98 |
| Asset Turnover Ratio (%) | 1.23 | 1.22 | 1.18 | 0.96 | 1.13 |
| Current Ratio (X) | 2.03 | 2.06 | 1.90 | 1.76 | 1.59 |
| Quick Ratio (X) | 1.25 | 1.10 | 1.12 | 1.07 | 0.86 |
| Inventory Turnover Ratio (X) | 3.20 | 2.86 | 2.81 | 2.21 | 3.22 |
| Interest Coverage Ratio (X) | 3.47 | 2.76 | 2.68 | 1.78 | 2.29 |
| Interest Coverage Ratio (Post Tax) (X) | 2.55 | 2.04 | 2.01 | 1.39 | 1.83 |
| Enterprise Value (Cr.) | 33.89 | 60.21 | 36.79 | 54.94 | 0.00 |
| EV / Net Operating Revenue (X) | 0.40 | 0.75 | 0.44 | 0.84 | 0.00 |
| EV / EBITDA (X) | 7.33 | 11.34 | 6.71 | 15.26 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.28 | 0.59 | 0.29 | 0.61 | 0.00 |
| Price / BV (X) | 0.65 | 1.36 | 0.73 | 1.28 | 0.00 |
| Price / Net Operating Revenue (X) | 0.28 | 0.59 | 0.29 | 0.61 | 0.00 |
| EarningsYield | 0.08 | 0.04 | 0.08 | 0.02 | 0.00 |
After reviewing the key financial ratios for Adeshwar Meditex Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 5. It has increased from 1.39 (Mar 24) to 1.43, marking an increase of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 5. It has increased from 1.39 (Mar 24) to 1.43, marking an increase of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.78. This value is below the healthy minimum of 3. It has decreased from 1.81 (Mar 24) to 1.78, marking a decrease of 0.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.61. It has increased from 24.19 (Mar 24) to 25.61, marking an increase of 1.42.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.61. It has increased from 24.19 (Mar 24) to 25.61, marking an increase of 1.42.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 58.01. It has increased from 55.33 (Mar 24) to 58.01, marking an increase of 2.68.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.21. This value is within the healthy range. It has decreased from 3.68 (Mar 24) to 3.21, marking a decrease of 0.47.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.86. This value is within the healthy range. It has decreased from 3.26 (Mar 24) to 2.86, marking a decrease of 0.40.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.94. This value is within the healthy range. It has increased from 1.93 (Mar 24) to 1.94, marking an increase of 0.01.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 2. It has increased from 1.39 (Mar 24) to 1.43, marking an increase of 0.04.
- For PBDIT Margin (%), as of Mar 25, the value is 5.52. This value is below the healthy minimum of 10. It has decreased from 6.64 (Mar 24) to 5.52, marking a decrease of 1.12.
- For PBIT Margin (%), as of Mar 25, the value is 4.93. This value is below the healthy minimum of 10. It has decreased from 5.89 (Mar 24) to 4.93, marking a decrease of 0.96.
- For PBT Margin (%), as of Mar 25, the value is 3.33. This value is below the healthy minimum of 10. It has decreased from 3.48 (Mar 24) to 3.33, marking a decrease of 0.15.
- For Net Profit Margin (%), as of Mar 25, the value is 2.46. This value is below the healthy minimum of 5. It has decreased from 2.51 (Mar 24) to 2.46, marking a decrease of 0.05.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.58. This value is below the healthy minimum of 15. It has decreased from 5.75 (Mar 24) to 5.58, marking a decrease of 0.17.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.49. This value is within the healthy range. It has decreased from 12.96 (Mar 24) to 10.49, marking a decrease of 2.47.
- For Return On Assets (%), as of Mar 25, the value is 2.86. This value is below the healthy minimum of 5. It has decreased from 3.13 (Mar 24) to 2.86, marking a decrease of 0.27.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.03 (Mar 24) to 0.05, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.33. This value is within the healthy range. It has decreased from 0.39 (Mar 24) to 0.33, marking a decrease of 0.06.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.23. It has increased from 1.22 (Mar 24) to 1.23, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 2.03. This value is within the healthy range. It has decreased from 2.06 (Mar 24) to 2.03, marking a decrease of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 1.25. This value is within the healthy range. It has increased from 1.10 (Mar 24) to 1.25, marking an increase of 0.15.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.20. This value is below the healthy minimum of 4. It has increased from 2.86 (Mar 24) to 3.20, marking an increase of 0.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.47. This value is within the healthy range. It has increased from 2.76 (Mar 24) to 3.47, marking an increase of 0.71.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.55. This value is below the healthy minimum of 3. It has increased from 2.04 (Mar 24) to 2.55, marking an increase of 0.51.
- For Enterprise Value (Cr.), as of Mar 25, the value is 33.89. It has decreased from 60.21 (Mar 24) to 33.89, marking a decrease of 26.32.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.40, marking a decrease of 0.35.
- For EV / EBITDA (X), as of Mar 25, the value is 7.33. This value is within the healthy range. It has decreased from 11.34 (Mar 24) to 7.33, marking a decrease of 4.01.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 24) to 0.28, marking a decrease of 0.31.
- For Price / BV (X), as of Mar 25, the value is 0.65. This value is below the healthy minimum of 1. It has decreased from 1.36 (Mar 24) to 0.65, marking a decrease of 0.71.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 24) to 0.28, marking a decrease of 0.31.
- For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.08, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Adeshwar Meditex Ltd:
- Net Profit Margin: 2.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.49% (Industry Average ROCE: 13.22%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.58% (Industry Average ROE: 10.35%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.55
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.25
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 15.8 (Industry average Stock P/E: 24.45)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.33
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.46%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | Gala 111 Lok Centre, MarolMaroshi Road, Mumbai Maharashtra 400059 | adeshwarmedi@gmail.com http://www.adeshwarmeditex.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Abhinandan Nagaraja Rao | Chairman & Wholetime Director |
| Ms. Ashalata Baburao Raut | Managing Director |
| Mr. Krishnojirao Nagaraja Rao | Whole Time Director |
| Mr. Shailesh Vinayak Rajpure | Executive Director |
| Mr. Benegal Parameshwara Udpa | Ind. Non-Executive Director |
| Mr. Arun Koli | Ind. Non-Executive Director |
| Mr. Prithvi Sanjay Singh | Non Executive Director |
FAQ
What is the intrinsic value of Adeshwar Meditex Ltd?
Adeshwar Meditex Ltd's intrinsic value (as of 18 October 2025) is 18.19 which is 16.56% lower the current market price of 21.80, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 31.4 Cr. market cap, FY2025-2026 high/low of 26.5/15.0, reserves of ₹22.53 Cr, and liabilities of 72.20 Cr.
What is the Market Cap of Adeshwar Meditex Ltd?
The Market Cap of Adeshwar Meditex Ltd is 31.4 Cr..
What is the current Stock Price of Adeshwar Meditex Ltd as on 18 October 2025?
The current stock price of Adeshwar Meditex Ltd as on 18 October 2025 is 21.8.
What is the High / Low of Adeshwar Meditex Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Adeshwar Meditex Ltd stocks is 26.5/15.0.
What is the Stock P/E of Adeshwar Meditex Ltd?
The Stock P/E of Adeshwar Meditex Ltd is 15.8.
What is the Book Value of Adeshwar Meditex Ltd?
The Book Value of Adeshwar Meditex Ltd is 25.6.
What is the Dividend Yield of Adeshwar Meditex Ltd?
The Dividend Yield of Adeshwar Meditex Ltd is 0.00 %.
What is the ROCE of Adeshwar Meditex Ltd?
The ROCE of Adeshwar Meditex Ltd is 8.27 %.
What is the ROE of Adeshwar Meditex Ltd?
The ROE of Adeshwar Meditex Ltd is 5.51 %.
What is the Face Value of Adeshwar Meditex Ltd?
The Face Value of Adeshwar Meditex Ltd is 10.0.